Atnahs Pharma’s $350 Million Acquisition of AstraZeneca’s Assets

Paolo Bossi

Latham & Watkins advised Atnahs Pharma in the transaction. AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Paolo Bossi

…

This content is for Standard 1 Year members only.
Login Join Now